According to TrimGen, its eQ-PCR LC warfarin genotyping assay will be used as an aid in the identification of patients who may be at risk of warfarin sensitivity.
Howard Doong of TrimGen, said: “The FDA approval is an important milestone for TrimGen. It indicates that our eQ-PCR technology has met the regulatory challenges; our efforts warrant not only a simple, accurate diagnostic test but also the future commercial success of the company.”